TP53 and breast cancer: In p53-mutated breast cancer, ERβ1 inhibits the proliferative and migratory activity of TNBC cells by suppressing the oncogenic function of mutant p53 (Bado et al., 2016), an effect that may be further enhanced by tamoxifen treatment (Scarpetti et al., 2023).